ACT IMMEDIATELY TO STOP ANTIBIOTIC RESISTANCE

- Optimization of critically ill patient management
- Effective rapid screening of colonized or infected subjects before hospitalization
- Possibility to promptly isolate the patient
- Compliance with the requirements of the SEPSIS Improvement and Antimicrobial Stewardship Programs
- Reduction of hospitalization
- Decrease in prescriptions of unnecessary antibiotics
- Reduction in the incidence of hospital acquired and multi resistant infections

ECONOMIC **ADVANTAGES**

LAB WORKFLOW

IMPACT

HEALTHCARE

BENEFITS

• Fully automation

- Reduced workloads and hands on time
- Method standardization
- Simultaneous management of multiple tests
- Complete integration of ALIFAX technology with the current methods used in the laboratory

PRODUCT	CODE	•	Liquid	Dry
HB&L VRE KIT	SI 1001.910-L	•		
HB&L CARBAPENEMASE KIT	SI 1001.950	•	•	
HB&L ESBL/AmpC SCREENING KIT	SI 1001.930-L	•	•	
HB&L ESBL/AmpC SCREENING KIT	SI 1001.930			•
HB&L MRSA KIT	SI 1001.900-L		•	

CE - IVD Marked, for professional use only

HB&L MRSA KIT

Due to regulatory requirements, the products listed herein are available for sale in any relevant Country territory provided that they have been registered according to the applicable domestic law. The products listed herein may have incurred changes with respect to the last available edition.

SI 1001.900

RAPID AND AUTOMATED PHENOTYPIC SCREENING

Bibliography available at www.alifax.com

ALIFAX S.r.l.

Via Petrarca, 2/1 - Polverara (PD) - Italy - (+39) 049 0992000 | info@alifax.com | www.alifax.com Entered in Padova companies register at the n. 04337640280. Company stock € 10.000.000 entirely deposited. Company with single partner and subjected to direction and coordination of Alifax Holding S.p.A.





ADRO **SCREENING KITS**

ON POSITIVE BLOOD CULTURE AND SWABS



MULTI DRUG RESISTANT ORGANISMS

Rapid and automated phenotypic screening

www.alifax.com



ADRO RAPID PHENOTYPIC SCREENING

RVEILL

MDRO infections represent a growing global health problem, further intensified in recent years by the pandemic, which due to an unpredictable emergency has increased the selective pressure and decreased the active surveillance in the hospital environment.

Alarming increase in resistant infections during hospitalization from 2019 to 2020*

Carbapenem-resistant Enterobacterales ESBL-producing Enterobacterales Vancomycin-resistant Enterococcus Methicillin-resistant Staphylococcus aureus

It is more urgent than ever to prioritize efforts towards resistance containment and support the One Health program to improve the detection, characterization and rapid response to emerging AMR.

Swab

35%

32%

14%

13%

STOP SPREAD OF RESISTANCES

The detection of resistant bacteria in swab samples is an effective screening of carriers to prevent the microorganism spread, quickly identify and isolate patients with serious infections, support patient management with personalized therapy, as well as promptly control the outbreaks.

	٢	
ESBL/AmpC	•	•
CRE	•	
VRE	•	
MRSA		•

- Fast results
- Automated reading
- High Sensitivity and NPV
- Easy interpretation of results: **negative** or **positive**
- Automatic screening available on HB&L, ALFRED 60/AST and fully automated workflow on SIDECAR

RESULTS

Blood Culture

U



Bloodstream infections caused by resistant microorganisms are one of the most potentially lifethreatening infections associated with high morbidity and mortality representing a real challenge for clinicians.

The New applications of Alifax MDRO screening kits for positive blood culture, support clinicians with fast and accurate information for the management of critically ill patients and could represent a key component of SEPSIS Improvement Programs and Antimicrobial Stewardship Programs to fight resistances and optimize outcomes.



The only **phenotypic tests** that provide results in a **few hours along** with real-time growth curves, performances superior to direct culture and **bacterial yield** for further confirmatory tests.

